Earnings Presentation Materials for the First Quarter of the Fiscal Year Ending March 2027 | Japan Tissue Engineering Co.,Ltd. (7774) timely disclosure

Worth reading

64In focus

Scored from 4 of 6 sections

Direction

Improvement

Direction inferred from the company’s description.

Scale

340

¥ million (year-on-year increase in revenue)

Wording

Conditional

How definitive the wording is.

Contents of this document

Financial Results PresentationFirst quarter of the fiscal year ending March 20278 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales766 Millions of yen+80.0%

Operating profit59 Millions of yen

Ordinary income63 Millions of yen

Net income52 Millions of yen

Selling, general and administrative expenses453 Millions of yen

Results for the three months of the current quarter

Net Sales

766 Millions of yen

Gross profit

512 Millions of yen

Operating profit (loss)

59 Millions of yen

Ordinary profit or loss

63 Millions of yen

Net income (loss) for the current fiscal year

52 Millions of yen

Full-year earnings forecast

Regenerative medicine products revenue

2,070 Millions of yen

Skin-related revenue

1,070 Millions of yen

Cartilage-related revenue

900 Millions of yen

Corneal-related revenue

100 Millions of yen

Regenerative medicine contract services revenue

640 Millions of yen

Labsite business revenue

360 Millions of yen

Total revenue

3,070 Millions of yen

Gross profit

2,000 Millions of yen

Selling, general and administrative expenses

1,900 Millions of yen

Operating profit (loss)

100 Millions of yen

Ordinary profit or loss

110 Millions of yen

Net income (loss) for the current fiscal year

100 Millions of yen

What the company explained in this material

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

JACE revenue140 Millions of yen
Teijin contract revenue-46 Millions of yen
JACC revenue177 Millions of yen
JASMINE revenue12 Millions of yen
Nepic and Ocural revenue9 Millions of yen
General customer contract revenue41 Millions of yen
Labsite business5 Millions of yen
European Expansion-35 Millions of yen
Variable costs-50 Millions of yen
Efficiency initiatives15 Millions of yen

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

The forecast assumes that the milestone from the Teijin contract will be recognized in the fourth quarter.

New initiatives

Expanding the number of facilities using JACC through a sales partnership with Osferion Biomaterials Co., Ltd.
Establishment of the German subsidiary Japan Tissue Engineering Europe GmbH
Building a local production and stable supply structure through a partnership with a German shared laboratory
Development toward the launch of an intestinal epithelial model for research use
Progress in developing new pipeline products, including Allo-JaCE03 and JPCAR019
Establishment of foundational technology for hair follicle organoids

Key KPIsA metric the company considers important as a management benchmark.

JACC first-quarter orders111 Example
Cumulative JACC orders for the current fiscal year (including orders received from the second quarter onward)220 Example
Number of facilities under contract for JACC143 Facility
JASMINE first-quarter orders9 Example
Cumulative JASMINE orders for the current fiscal year26 Example
Number of facilities participating in hospital-clinic collaboration for JASMINE52 Facility
Number of recurring Labsite customers8 companies

Segment results

Regenerative medicine products business
Net Sales603 Millions of yen
Year-on-Year Change in Revenue (%)130
Operating profit (loss)240 Millions of yen
Year-on-year change in operating income (loss)205 Millions of yen
Regenerative medicine contract services business
Net Sales94 Millions of yen
Year-on-Year Change in Revenue (%)-5
Operating profit (loss)45 Millions of yen
Year-on-year change in operating income (loss)-5 Millions of yen
Labsite business
Net Sales68 Millions of yen
Year-on-Year Change in Revenue (%)8
Operating profit (loss)14 Millions of yen
Year-on-year change in operating income (loss)-4 Millions of yen

Medium-term management plan targets

TargetAchieve revenue of ¥5 billion
TargetAnnual JACC revenue of ¥3 billion
Target1,000 JACC cases annually
Target fiscal yearIn several years

Market Size / Share

13,500 cases/year
DetailsAnnual number of osteotomy procedures
10,000,000 people
DetailsNumber of patients with osteoarthritis of the knee
1,000 People/year
DetailsMarket estimated from JACC eligibility criteria
60 %
DetailsPercentage of osteotomy procedures performed in combination with JACC

Number of employees

Number of Employees200 people

Record dateEnd of March 2026

Contents of this document
Item	Details
Document type	Financial Results Presentation
Fiscal Period Covered	First quarter of the fiscal year ending March 2027
Net Sales	766 Millions of yen (YoY +80.0%)
Operating profit	59 Millions of yen
Ordinary income	63 Millions of yen
Net income	52 Millions of yen
Selling, general and administrative expenses	453 Millions of yen
Results for the three months of the current quarter	Net Sales 766 Millions of yen / Gross profit 512 Millions of yen / Operating profit (loss) 59 Millions of yen / Ordinary profit or loss 63 Millions of yen / Net income (loss) for the current fiscal year 52 Millions of yen
Full-year earnings forecast	Regenerative medicine products revenue 2,070 Millions of yen / Skin-related revenue 1,070 Millions of yen / Cartilage-related revenue 900 Millions of yen / Corneal-related revenue 100 Millions of yen / Regenerative medicine contract services revenue 640 Millions of yen / Labsite business revenue 360 Millions of yen / Total revenue 3,070 Millions of yen / Gross profit 2,000 Millions of yen / Selling, general and administrative expenses 1,900 Millions of yen / Operating profit (loss) 100 Millions of yen / Ordinary profit or loss 110 Millions of yen / Net income (loss) for the current fiscal year 100 Millions of yen
Segment results	Segment Regenerative medicine products business / Net Sales 603 Millions of yen / Year-on-Year Change in Revenue (%) 130 / Operating profit (loss) 240 Millions of yen / Year-on-year change in operating income (loss) 205 Millions of yen, Segment Regenerative medicine contract services business / Net Sales 94 Millions of yen / Year-on-Year Change in Revenue (%) -5 / Operating profit (loss) 45 Millions of yen / Year-on-year change in operating income (loss) -5 Millions of yen, Segment Labsite business / Net Sales 68 Millions of yen / Year-on-Year Change in Revenue (%) 8 / Operating profit (loss) 14 Millions of yen / Year-on-year change in operating income (loss) -4 Millions of yen
Breakdown of Factors Affecting the Change	Factors JACE revenue / Amount 140 Millions of yen, Factors Teijin contract revenue / Amount -46 Millions of yen, Factors JACC revenue / Amount 177 Millions of yen, Factors JASMINE revenue / Amount 12 Millions of yen, Factors Nepic and Ocural revenue / Amount 9 Millions of yen, Factors General customer contract revenue / Amount 41 Millions of yen, Factors Labsite business / Amount 5 Millions of yen, Factors European Expansion / Amount -35 Millions of yen, Factors Variable costs / Amount -50 Millions of yen, Factors Efficiency initiatives / Amount 15 Millions of yen
Key KPIs	Indicator name JACC first-quarter orders / Value 111 Example / Year on year against the same period last year Not disclosed, Indicator name Cumulative JACC orders for the current fiscal year (including orders received from the second quarter onward) / Value 220 Example / Year on year against the same period last year Not disclosed, Indicator name Number of facilities under contract for JACC / Value 143 Facility / Year on year against the same period last year Not disclosed, Indicator name JASMINE first-quarter orders / Value 9 Example / Year on year against the same period last year Not disclosed, Indicator name Cumulative JASMINE orders for the current fiscal year / Value 26 Example / Year on year against the same period last year Not disclosed, Indicator name Number of facilities participating in hospital-clinic collaboration for JASMINE / Value 52 Facility / Year on year against the same period last year Not disclosed, Indicator name Number of recurring Labsite customers / Value 8 companies / Year on year against the same period last year Not disclosed
Number of employees	Number of Employees 200 people / Record date End of March 2026
Assumptions Underlying the Business Outlook	The forecast assumes that the milestone from the Teijin contract will be recognized in the fourth quarter.
Medium-term management plan targets	Target Achieve revenue of ¥5 billion / Target fiscal year Not disclosed, Target Annual JACC revenue of ¥3 billion / Target fiscal year Not disclosed, Target 1,000 JACC cases annually / Target fiscal year In several years
Market Size / Share	13,500 cases/year, 10,000,000 people, 1,000 People/year, 60 %
New initiatives	Expanding the number of facilities using JACC through a sales partnership with Osferion Biomaterials Co., Ltd., Establishment of the German subsidiary Japan Tissue Engineering Europe GmbH, Building a local production and stable supply structure through a partnership with a German shared laboratory, Development toward the launch of an intestinal epithelial model for research use, Progress in developing new pipeline products, including Allo-JaCE03 and JPCAR019, Establishment of foundational technology for hair follicle organoids

Items this document does not state (14)

Gross Profit MarginOperating profit marginProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Orders for JACC increased significantly following the expansion of its indication to osteoarthritis of the knee, and the number of facilities using it also increased. Revenue was also supported by a recovery in the number of eligible cases for JACE, expansion of facilities and patient education for JASMINE, and progress into later development phases for contract projects from general customers. Contract work for Teijin, however, declined as the provision of know-how ran its course.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.